Brokerages expect Penumbra Inc (NYSE:PEN) to announce earnings per share (EPS) of ($0.01) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Penumbra’s earnings. The lowest EPS estimate is ($0.04) and the highest is $0.01. Penumbra posted earnings per share of ($0.08) in the same quarter last year, which would suggest a positive year-over-year growth rate of 87.5%. The company is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, February 27th.
According to Zacks, analysts expect that Penumbra will report full-year earnings of ($0.15) per share for the current financial year, with EPS estimates ranging from ($0.17) to ($0.13). For the next year, analysts forecast that the firm will post earnings of $0.05 per share, with EPS estimates ranging from $0.01 to $0.11. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Penumbra.
PEN has been the subject of several recent research reports. BMO Capital Markets lifted their target price on shares of Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Canaccord Genuity raised their price objective on shares of Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. JPMorgan Chase & Co. lowered shares of Penumbra from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Zacks Investment Research lowered shares of Penumbra from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Finally, William Blair started coverage on shares of Penumbra in a research report on Wednesday. They issued an “outperform” rating for the company. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Penumbra has an average rating of “Hold” and an average price target of $111.50.
Several hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its position in Penumbra by 10.8% during the second quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock valued at $226,000 after purchasing an additional 250 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Penumbra by 45.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,691 shares of the company’s stock valued at $159,000 after purchasing an additional 532 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in Penumbra by 5.7% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,544 shares of the company’s stock valued at $1,180,000 after purchasing an additional 680 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in Penumbra by 5.5% during the third quarter. State Board of Administration of Florida Retirement System now owns 13,975 shares of the company’s stock valued at $1,262,000 after purchasing an additional 730 shares during the last quarter. Finally, Raymond James & Associates lifted its position in Penumbra by 10.5% during the fourth quarter. Raymond James & Associates now owns 8,351 shares of the company’s stock valued at $786,000 after purchasing an additional 792 shares during the last quarter. Institutional investors own 71.09% of the company’s stock.
Penumbra (NYSE PEN) traded up $2.07 on Monday, hitting $100.77. 21,485 shares of the stock traded hands, compared to its average volume of 275,565. The stock has a market capitalization of $3,371.80, a P/E ratio of -448.64, a price-to-earnings-growth ratio of 106.45 and a beta of 0.19. Penumbra has a 52-week low of $74.15 and a 52-week high of $116.35.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.